Research programme: antibody-drug conjugate therapeutics - CytomX/ImmunoGen

Drug Profile

Research programme: antibody-drug conjugate therapeutics - CytomX/ImmunoGen

Alternative Names: EpCAM PDC; EpCAM Probody drug conjugate; Probody™-drug conjugates - CytomX/ImmunoGen

Latest Information Update: 19 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CytomX Therapeutics; ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 19 Sep 2018 Preclinical development in Solid tumours is ongoing in USA (Immunogen pipeline, CytomX pipeline, September 2018)
  • 11 Dec 2015 Preclinical trials in Solid tumours in USA
  • 09 Jan 2014 Early research in Cancer in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top